Compare Charles River Laboratories Intl. Inc (CRL) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Intel Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $300.35 (market cap $14.23B), while Intel Corp trades at $106.03 (market cap $566.04B). The key difference: Intel Corp is far larger — about 39.8× Charles River Laboratories Intl. Inc's market cap, and Intel Corp pays a 2.24% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Intel Corp for 116 Days on average.
| CRL | INTC | |
|---|---|---|
Market Cap | $14.23B | $566.04B |
Volume | 1,176,885 | 118,475,837 |
Sector | Health | Technology |
52-Week High | $310.77 | $140.94 |
52-Week Low | $149.93 | $33.62 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $17.06B | $586.85B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Intel (INTC) trades at $113.12, up 0.55% on the day, with a bullish technical signal supported by moving averages. Recent earnings beats and a 222% stock surge in 2026 reflect strong AI momentum and foundry growth, though negative net income and high valuation ratios signal caution. The company's cash flow improved in 2025, but competitive pressures and margin challenges persist.
The outlook hinges on Intel's foundry turnaround gaining traction, with revenue growth and external customer adoption as key catalysts. Risks include intense competition, high debt, and execution uncertainty. Analyst consensus is mixed, with a hold rating dominant, suggesting cautious optimism amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
